Evaluating immune biomarkers overlapping in tumor and CSF in diffuse midline glioma (DMG)

The potential of this project is to identify a therapeutic biomarker – a biological signal that is released as a response to treatment such as radiation, chemotherapy, or immunotherapy – in the cerebrospinal fluid (CSF) of patients with Diffuse Midline Glioma. In assessing unique biological signals that appear after treatment administration in BOTH the CSF and at the tumor site, we can then use the CSF – which circulates around the brain and spinal cord – to map patients’ responses to treatment instead of using tumor tissue itself, which requires a more invasive and limited procedure.